Grifols (GRFS) Invested Capital (2009 - 2025)
Grifols' (GRFS) quarterly Invested Capital came in at $11.2 billion in Q4 2025, up 1024.66% YoY from $998.1 million in Q4 2024, and up 1024.66% on a QoQ basis from $998.1 million in Q4 2024.
Grifols (GRFS) Invested Capital (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Invested Capital data on file, last reported at $11.2 billion in Q4 2025.
- Quarterly Invested Capital rose 1024.66% year-over-year to $11.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.1 billion (down 1.27% YoY) and the FY2025 annual result came in at $11.2 billion, up 1024.66% from the prior year.
- Invested Capital advanced to $11.2 billion in Q4 2025, from $998.1 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $11.9 billion in Q4 2023 to a low of $998.1 million in Q4 2024.
- A 5-year average of $9.4 billion and a median of $11.2 billion in 2025 frame the typical range for Invested Capital.
- Annual changes were most pronounced in 2024 — Invested Capital sank 91.61% — and 2025, when it soared 1024.66%.
- Tracing GRFS's Invested Capital over 5 years: stood at $11.7 billion in 2021, then fell by 6.01% to $11.0 billion in 2022, then climbed by 8.39% to $11.9 billion in 2023, then slumped by 91.61% to $998.1 million in 2024, then soared by 1024.66% to $11.2 billion in 2025.
- The last three Invested Capital figures came in at $11.2 billion (Q4 2025), $998.1 million (Q4 2024), and $11.9 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 11.69 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 8.34 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 32.24 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 5.45 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 2.41 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -7.25 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 985.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.22 Bn |
| Dec 31, 2024 | 998.07 Mn |
| Dec 31, 2023 | 11.90 Bn |
| Dec 31, 2022 | 10.97 Bn |
| Dec 31, 2021 | 11.68 Bn |
| Dec 31, 2020 | 8.38 Bn |
| Sep 30, 2020 | 373.69 Mn |
| Mar 31, 2020 | 365.85 Mn |
| Dec 31, 2019 | 7.98 Bn |
| Sep 30, 2019 | 462.26 Mn |
| Dec 31, 2018 | 7.28 Bn |
| Sep 30, 2018 | 287.95 Mn |
| Jun 30, 2018 | 244.77 Mn |
| Mar 31, 2018 | 405.38 Mn |
| Dec 31, 2017 | 7.13 Bn |
| Jun 30, 2017 | 163.35 Mn |
| Dec 31, 2016 | 5.34 Bn |
| Sep 30, 2016 | 248.78 Mn |
| Jun 30, 2016 | 243.09 Mn |
| Mar 31, 2016 | 15.11 Mn |